How Structural Biologists and the Protein Data Bank Contributed to Recent FDA New Drug Approvals
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Discovery and development of 210 new molecular entities [NMEs, new drugs] approved by the US Food and Drug Administration 2010–2016 was facilitated by 3D structural information generated by structural biologists worldwide and distributed on an open access basis by the Protein Data Bank [PDB]. The molecular targets for 94% of these NMEs are known. The PDB archive contains 5,914 structures containing one of the known targets and/or a new drug, providing structural coverage for 88% of the recently approved NMEs across all therapeutic areas. More than half of the 5,914 structures were published and made available by the PDB at no charge with no restrictions on usage >10 years before drug approval. Citation analyses revealed that these 5,914 PDB structures significantly impacted the very large body of publicly-funded research reported in publications on the NME targets that motivated biopharmaceutical company investment in discovery and development programs that produced the NMEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The FAIR Guiding Principles for scientific data management and stewardship
Wilkinson, M. D., Dumontier, M., Aalbersberg, I. J., Appleton, G., Axton, M., Baak, A., Blomberg, N., Boiten, J.-W., da Silva Santos, L. B., Bourne, P. E., et al. (2016) · Scientific Data · doi:10.1038/sdata.2016.18 · Cited by 18,423
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359 · cited 1×
“Galkina Cleary et al. (2018) et al., 2016).”
Announcing the worldwide Protein Data Bank
Berman, H., Henrick, K., & Nakamura, H. (2003) · Nature Structural & Molecular Biology · doi:10.1038/nsb1203-980 · Cited by 3,093
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939 · cited 1×
“These new drugs came primarily from phenotypic screening, which remains an important means of identifying lead compounds for drug discovery (Moffat et al., 2017).”
BackgroundContribution of NIH funding to new drug approvals 2010–2016
Galkina Cleary, E., Beierlein, J. M., Khanuja, N. S., McNamee, L. M., & Ledley, F. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1715368115 · Cited by 248
D3R grand challenge 2015: evaluation of protein-ligand pose and affinity predictions.
Gathiaka, S., Liu, S., Chiu, M., Yang, H., Stuckey, J. A., Kang, Y. N., Delproposto, J., Kubish, G., Dunbar, J. B., Carlson, H. A., et al. (2016) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-9946-8 · Cited by 207 · cited 1×
“…a large number of “post-competitive” co-crystal structures have been generously donated by biopharmaceutical companies to the NIGMS-NIH funded Drug Design Data Resource [D3R; drugdesigndata.org] for use in blind challenges of computational docking/scoring of ligands (Gathiaka et al., 2016).”
BackgroundSelf-citationSteensgaard, D. B., Schluckebier, G., Strauss, H. M., Norrman, M., Thomsen, J. K., Friderichsen, A. V., Havelund, S., & Jonassen, I. (2013) · Biochemistry · doi:10.1021/bi3008609 · Cited by 86
Beierlein, J. M., McNamee, L. M., Walsh, M. J., Kaitin, K. I., DiMasi, J. A., & Ledley, F. D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.06.001 · Cited by 24 · cited 1×
“Finally, our analyses of the impact of 3D structure provide further support for the view that life-changing biomedical innovations (e.g., NME approvals) depend critically on open sharing of data within scientific ecosystems and generation of knowledge therefrom (Beierlein et al., 2017).”
Background
Cited by
Burley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chen, L., Crichlow, G. V., Christie, C. H., Dalenberg, K., Di Costanzo, L., Duarte, J. M., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1038 · Cited by 1,581
Self-citationBurley, S. K., Bhikadiya, C., Bi, C., Bittrich, S., Chao, H., Chen, L., Craig, P. A., Crichlow, G. V., Dalenberg, K., Duarte, J. M., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkac1077 · Cited by 887
Self-citationRCSB Protein Data Bank: Enabling biomedical research and drug discovery
Goodsell, D. S., Zardecki, C., Di Costanzo, L., Duarte, J. M., Hudson, B. P., Persikova, I., Segura, J., Shao, C., Voigt, M., Westbrook, J. D., et al. (2020) · Protein Science · doi:10.1002/pro.3730 · Cited by 353
Self-citationBuya, A. B., Beloqui, A., Memvanga, P. B., & Préat, V. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121194 · Cited by 301
Structural basis for the action of the drug trametinib at KSR-bound MEK
Khan, Z. M., Real, A. M., Marsiglia, W. M., Chow, A., Duffy, M. E., Yerabolu, J. R., Scopton, A. P., & Dar, A. C. (2020) · Nature · doi:10.1038/s41586-020-2760-4 · Cited by 178
Race to the Bottom: Competition and Quality in Science
Hill, R., & Stein, C. (2025) · The Quarterly Journal of Economics · doi:10.1093/qje/qjaf010 · Cited by 40
Metadata
- Authors
- Westbrook, J. D., & Burley, S. K.
- Venue
- Structure
- Publisher
- Elsevier BV
- Published
- 2019-02
- Volume
- 27
- Issue
- 2
- Pages
- 211-217
- ISSN
- 0969-2126 (ISSN-L)
- OpenAlex
- W2907126701
- Cited by
- 88
- References
- 8
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.